pamidronate has been researched along with Brittle Bone Disease in 163 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous pamidronate is widely used to treat children with osteogenesis imperfecta (OI)." | 9.22 | Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta. ( Andrade, MC; Carvalhaes, JT; Glorieux, FH; Lazaretti-Castro, M; Palomo, T; Peters, BS; Rauch, F; Reis, FA, 2016) |
| "Pamidronate (PAM) infusion is the standard treatment in children with osteogenesis imperfecta (OI)." | 9.16 | Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. ( Barros, ER; de Oliveira, TP; Lazaretti-Castro, M; Saraiva, GL, 2012) |
| "Pamidronate is widely used to treat pediatric patients with osteogenesis imperfecta (OI)." | 9.15 | Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients. ( Aström, E; Heino, TJ; Laurencikas, E; Sävendahl, L; Söderhäll, S, 2011) |
| "Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI)." | 9.14 | Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. ( Cheung, MS; Glorieux, FH; Rauch, F, 2009) |
| "Zoledronic acid is at least as effective as pamidronate as treatment for paediatric osteoporosis, and has a similar safety profile." | 9.14 | Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. ( Brown, JJ; Zacharin, MR, 2009) |
| "Current regimens of intravenous pamidronate for infants and children with osteogenesis imperfecta (OI) typically deliver 3-12 mg/kg/year of drug." | 9.13 | Two doses of pamidronate in infants with osteogenesis imperfecta. ( Bishop, NJ; Senthilnathan, S; Walker, E, 2008) |
| "Cyclic intravenous pamidronate treatment is widely used for symptomatic therapy of osteogenesis imperfecta (OI)." | 9.13 | Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. ( Alikasifoglu, A; Andiran, N; Gonc, N; Kandemir, N; Ozon, A; Yordam, N, 2008) |
| "Cyclical iv pamidronate is a widely used symptomatic therapy of osteogenesis imperfecta (OI)." | 9.12 | Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. ( Glorieux, FH; Land, C; Munns, C; Rauch, F, 2006) |
| "This analysis of 50 growing patients with osteogenesis imperfecta revealed that 2-4 years of pamidronate treatment lead to abnormalities in the shape of the distal femoral metaphyses." | 9.12 | Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. ( Glorieux, FH; Land, C; Rauch, F, 2006) |
| "Cyclical intravenous pamidronate therapy increases bone mass in children with osteogenesis imperfecta (OI), but the effect on the intrinsic material properties of bone is unknown at present." | 9.12 | Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. ( Fratzl, P; Fratzl-Zelman, N; Glorieux, FH; Klaushofer, K; Rauch, F; Roschger, P; Schöberl, T; Weber, M, 2006) |
| "To evaluate the functional abilities and the level of ambulation during pamidronate therapy in children with moderate to severe osteogenesis imperfecta." | 9.12 | Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. ( Glorieux, FH; Land, C; Montpetit, K; Rauch, F; Ruck-Gibis, J, 2006) |
| "Children with the severe forms of osteogenesis imperfecta have in several studies been treated with intravenous pamidronate, but there are only few reports of the effect of early treatment." | 9.12 | Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. ( Aström, E; Jorulf, H; Söderhäll, S, 2007) |
| "Cyclical intravenous treatment with pamidronate is of clinical benefit in children with moderate to severe osteogenesis imperfecta (OI) types I, III and IV, but there is no information on the effects of this treatment on the newly described OI type VI." | 9.12 | Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. ( Glorieux, FH; Land, C; Rauch, F; Travers, R, 2007) |
| "Pamidronate treatment has been shown to improve outcome in osteogenesis imperfecta (OI); however, factors influencing outcome are unclear." | 9.12 | Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome. ( Bajpai, A; Ghosh, M; Gupta, N; Kabra, M; Sharda, S, 2007) |
| "We evaluated the efficacy of a monthly infusion of pamidronate on the frequency of fractures, biochemical effects, and bone mineral density in children with osteogenesis imperfecta." | 9.12 | Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. ( Choi, JH; Shin, YL; Yoo, HW, 2007) |
| "Nine infants and young children with osteogenesis imperfecta (age range 1-35 months) were treated with intravenous pamidronate." | 9.11 | Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. ( DiMeglio, LA; Ford, L; McClintock, C; Peacock, M, 2004) |
| "Observations in small patient series indicate that infants with severe osteogenesis imperfecta (OI) benefit from treatment with cyclical intravenous pamidronate." | 9.11 | Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. ( Glorieux, FH; Munns, CF; Rauch, F; Travers, R, 2005) |
| "To evaluate the efficacy of pamidronate in protecting against fractures, increasing bone mineral density (BMD), and decreasing bone remodeling marker levels in children with osteogenesis imperFecta." | 9.10 | Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. ( Giraud, F; Meunier, PJ, 2002) |
| "A prospective open study was performed to determine the efficacy and safety of pamidronate in improving bone mineralisation and reducing fracture incidence in osteogenesis imperfecta (OI)." | 9.09 | Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. ( Lee, YS; Lim, LA; Loke, KY; Low, SL, 2001) |
| "In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6." | 9.08 | Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998) |
| "To verify radiomorphometric indices and fractal dimension (FD) in dental panoramic radiographs (DPRs) of children with different types of osteogenesis imperfecta (OI) and also to verify the effect of pamidronate (PAM) treatment in such panoramic analyses." | 7.83 | Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment. ( Acevedo, AC; Apolinário, AC; Castro, LC; de Melo, NS; de Paula, AP; de Paula, LM; de Souza Figueiredo, PT; Guimarães, AT; Leite, AF; Sindeaux, R, 2016) |
| "Pamidronate treatment in children with all types of OI increased LS BMD, decreased fracture rate, and improved vertebral compression fractures." | 7.83 | Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. ( Åström, E; Grigelioniene, G; Kindmark, A; Lindahl, K; Ljunggren, Ö; Malmgren, B; Rubin, CJ; Söderhäll, S, 2016) |
| "We hypothesized that mandibular cortical width (MCW) is smaller in children with osteogenesis imperfecta (OI) than in healthy children and that pamidronate can improve the cortical mandibular thickness." | 7.81 | Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta. ( Acevedo, AC; Apolinário, AC; Castro, LC; Figueiredo, PT; Guimarães, AT; Leite, AF; Melo, NS; Paula, AP; Paula, LM, 2015) |
| "Intravenous pamidronate has been used off-label in the treatment of severe osteogenesis imperfecta (OI) for almost 20 years." | 7.80 | Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. ( Bompadre, V; Sousa, T; White, KK, 2014) |
| "The six patients, who had bone fractures either in utero or in their 1st month of life, were treated with cyclic pamidronate from a mean age of 2." | 7.80 | Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta. ( Chien, CC; Chien, YH; Hwu, WL; Lee, CT; Lee, NC; Lin, CH; Peng, SF; Tsai, WY; Tung, YC, 2014) |
| "To assess the beneficial effect of intravenous pamidronate treatment in children with osteogenesis imperfecta (OI)." | 7.80 | Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta. ( Atta, I; Ibrahim, M; Iqbal, F; Khan, YN; Lone, SW; Raza, J, 2014) |
| "Evaluate clinical outcome of early cyclic intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta (OI), commenced before three years of age." | 7.79 | Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. ( Alcausin, MB; Ault, J; Bridge, C; Briody, J; Engelbert, RH; McQuade, M; Munns, CF; Pacey, V; Sillence, DO, 2013) |
| " To assess the role of biochemical bone markers in classification of children with osteogenesis imperfecta (OI), their possible association with vertebral compression fractures in milder forms of OI and their role in monitoring of intravenous pamidronate (APD) treatment." | 7.76 | Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. ( Aström, E; Eksborg, S; Magnusson, P; Söderhäll, S, 2010) |
| "Cyclical intravenous treatment with pamidronate is widely used to treat osteogenesis imperfecta (OI) types I, III, and IV, which are due to dominant mutations affecting collagen type I alpha chains." | 7.75 | Intravenous pamidronate in osteogenesis imperfecta type VII. ( Cheung, MS; Glorieux, FH; Rauch, F, 2009) |
| "To assess the long-term effect of pamidronate therapy on bone mineral metabolism and bone mineral density (BMD) in children with osteogenesis imperfecta (OI) and to evaluate BMD results with respect to national standards." | 7.74 | Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. ( Bas, F; Bundak, R; Darendeliler, F; Eryilmaz, SK; Gunoz, H; Poyrazoglu, S; Saka, N; Tutunculer, F, 2008) |
| "Information on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited." | 7.74 | Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta. ( Chang, CY; Chen, MR; Chuang, CK; Lin, HY; Lin, SP, 2008) |
| "Cyclical intravenous pamidronate is a widely used symptomatic therapy in moderate to severe osteogenesis imperfecta (OI)." | 7.74 | Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. ( Cheung, M; Cornibert, S; Glorieux, FH; Rauch, F, 2007) |
| "To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI)." | 7.74 | Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. ( Aström, E; Eliasson, AC; Löwing, K; Oscarsson, KA; Söderhäll, S, 2007) |
| "To study the efficacy of pamidronate in children with osteogenesis imperfecta (OI)." | 7.73 | Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. ( Arabi, A; Bensman, A; Filipe, G; Forin, V; Guigonis, V; Roux, C, 2005) |
| "Intravenous treatment with pamidronate is beneficial in children and adolescents with moderate to severe forms of osteogenesis imperfecta (OI) types I, III and IV, but there is little information on the effects of this treatment on the newly described OI type V." | 7.73 | The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. ( Glorieux, FH; Munns, C; Rauch, F; Travers, R; Zeitlin, L, 2006) |
| "Intravenous pamidronate treatment is beneficial to children and adolescents with osteogenesis imperfecta (OI), but the effects of prolonged therapy are not well characterized." | 7.73 | Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. ( Glorieux, FH; Rauch, F; Travers, R, 2006) |
| "Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data." | 7.73 | Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. ( Chan, B; Zacharin, M, 2006) |
| "The aim of this study was to evaluate the efficacy of pamidronate in the management of osteogenesis imperfecta patients." | 7.73 | Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study. ( Basha, NE; el-Sobky, MA; Hanna, AA; Said, MH; Tarraf, YN, 2006) |
| "Results in small patient series suggest that cyclical intravenous treatment with pamidronate can lead to reshaping of compressed vertebral bodies in children and adolescents with osteogenesis imperfecta (OI), but more detailed analyses are lacking." | 7.73 | Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. ( Glorieux, FH; Land, C; Munns, CF; Rauch, F; Sahebjam, S, 2006) |
| "Cyclical iv therapy with pamidronate improves the clinical course in children and adolescents with osteogenesis imperfecta (OI)." | 7.72 | Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. ( Glorieux, FH; Plotkin, H; Rauch, F; Travers, R; Zeitlin, L, 2003) |
| "Cyclical intravenous therapy with pamidronate improves the clinical course in children and adolescents with osteogenesis imperfecta (OI)." | 7.72 | Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. ( Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003) |
| "Treatment with pamidronate improves the clinical course in children with osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth." | 7.72 | Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. ( Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003) |
| "To examine changes in grip force during pamidronate therapy in children and adolescents with severe osteogenesis imperfecta (OI)." | 7.72 | Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. ( Bilodeau, N; Cloutier, S; Glorieux, FH; Montpetit, K; Plotkin, H; Rabzel, M; Rauch, F, 2003) |
| "This report aims to describe the adverse respiratory events associated with the first pamidronate cycle in four infants with severe osteogenesis imperfecta (OI) who were less than 2 years of age." | 7.72 | Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. ( Glorieux, FH; Mier, RJ; Munns, CF; Rauch, F, 2004) |
| "Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI)." | 7.72 | Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. ( Fassier, F; Glorieux, FH; Munns, CF; Rauch, F; Zeitlin, L, 2004) |
| "Cyclical pamidronate infusions increase bone mass in children suffering from osteogenesis imperfecta." | 7.71 | The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. ( Glorieux, FH; Plotkin, H; Rauch, F; Travers, R, 2002) |
| "Pamidronate seems to be useful in the treatment of patients with osteogenesis imperfecta." | 7.71 | Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. ( Escolá, J; González, E; Pavía, C; Ros, J; Valls, C; Villaronga, M, 2001) |
| "The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures." | 7.69 | Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. ( Ball, RJ; Smith, RA; Wilkinson, H; Williams, CJ, 1997) |
| "Three children with osteogenesis imperfecta, severe osteopenia, and repeated fractures were treated with cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) for a period ranging from 22 to 29 months." | 7.69 | Intravenous pamidronate treatment in osteogenesis imperfecta. ( Bembi, B; Bottega, M; Ceschel, S; Ciana, G; Martini, C; Parma, A; Zanatta, M, 1997) |
| "Pamidronate treatment led to significant increases in bone mineral density (BMD), measured by DXA, in the lumbar spine at 12 months (P = 0." | 6.71 | The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. ( Bober, M; Ernest, K; Fedarko, N; Gelman, R; McCarthy, EF; Rossiter, K; Santiago, HT; Shapiro, JR, 2003) |
| "Pamidronate treatment improves bone quality in children with mild types of OI." | 6.71 | Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004) |
| "Pamidronate treatment of severe forms of OI is an effective therapeutic modality to increase bone density, decrease fracture rate, increase mobility and improve quality of life, irrespective of the severity of the mutation or clinical phenotype." | 6.70 | Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. ( Bateman, J; Zacharin, M, 2002) |
| "Pamidronate treatment in severely affected OI patients under 3 yr of age is safe, increases BMD, and decreases fracture rate." | 6.69 | Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. ( Bishop, NJ; Glorieux, FH; Montpetit, K; Plotkin, H; Rauch, F; Ruck-Gibis, J; Travers, R, 2000) |
| "Osteogenesis imperfecta is characterised by low bone mineral density, bone fragility, fractures and deformity." | 5.62 | Intravenous pamidronate for treatment of osteogenesis imperfecta in Indian children. ( Goel, A; Johari, A; Shah, I; Shetty, NS, 2021) |
| "Pamidronate treatment significantly increased the Z score in all patients, and increases in the Z score did not correlate with the OI types, causative genes, or genotype." | 5.48 | Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta. ( Fujiwara, I; Kanno, J; Kure, S; Saito-Hakoda, A, 2018) |
| "Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI." | 5.46 | Therapy with pamidronate in children with osteogenesis imperfecta. ( Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017) |
| "Osteogenesis imperfecta is a heritable disorder of bone connective tissue." | 5.43 | Pamidronate treatment for osteogenesis imperfecta in black South Africans. ( Henderson, BD; Isaac, N; Khiba, S; Mabele, O; Mokoena, T; Nkayi, A, 2016) |
| "Pamidronate was administered in three-day cycles." | 5.42 | Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age. ( Ayoob, R; Bowden, SA; Ingraham, S; Kusumi, K; Mahan, JD, 2015) |
| "This report details the development of respiratory failure during the second infusion of pamidronate in a 3." | 5.40 | Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. ( Olson, JA, 2014) |
| "Pamidronate (PAM), which has to be administered as a 3-day course according to the original protocol by Glorieux, is the most frequently used therapy." | 5.37 | Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. ( Beccard, R; Demant, A; Fricke, O; Koerber, F; Palmisano, D; Schoenau, E; Semler, O, 2011) |
| "Bisphosphonates are now widely used to treat children with osteogenesis imperfecta (OI)." | 5.32 | Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. ( Arikoski, P; Bishop, NJ; Silverwood, B; Tillmann, V, 2004) |
| "Intravenous pamidronate is widely used to treat children with osteogenesis imperfecta (OI)." | 5.22 | Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta. ( Andrade, MC; Carvalhaes, JT; Glorieux, FH; Lazaretti-Castro, M; Palomo, T; Peters, BS; Rauch, F; Reis, FA, 2016) |
| "Pamidronate (PAM) infusion is the standard treatment in children with osteogenesis imperfecta (OI)." | 5.16 | Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. ( Barros, ER; de Oliveira, TP; Lazaretti-Castro, M; Saraiva, GL, 2012) |
| "Pamidronate is widely used to treat pediatric patients with osteogenesis imperfecta (OI)." | 5.15 | Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients. ( Aström, E; Heino, TJ; Laurencikas, E; Sävendahl, L; Söderhäll, S, 2011) |
| "Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI)." | 5.14 | Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate. ( Cheung, MS; Glorieux, FH; Rauch, F, 2009) |
| "Zoledronic acid is at least as effective as pamidronate as treatment for paediatric osteoporosis, and has a similar safety profile." | 5.14 | Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. ( Brown, JJ; Zacharin, MR, 2009) |
| "Current regimens of intravenous pamidronate for infants and children with osteogenesis imperfecta (OI) typically deliver 3-12 mg/kg/year of drug." | 5.13 | Two doses of pamidronate in infants with osteogenesis imperfecta. ( Bishop, NJ; Senthilnathan, S; Walker, E, 2008) |
| "Cyclic intravenous pamidronate treatment is widely used for symptomatic therapy of osteogenesis imperfecta (OI)." | 5.13 | Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. ( Alikasifoglu, A; Andiran, N; Gonc, N; Kandemir, N; Ozon, A; Yordam, N, 2008) |
| "Cyclical iv pamidronate is a widely used symptomatic therapy of osteogenesis imperfecta (OI)." | 5.12 | Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. ( Glorieux, FH; Land, C; Munns, C; Rauch, F, 2006) |
| "This analysis of 50 growing patients with osteogenesis imperfecta revealed that 2-4 years of pamidronate treatment lead to abnormalities in the shape of the distal femoral metaphyses." | 5.12 | Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. ( Glorieux, FH; Land, C; Rauch, F, 2006) |
| "Cyclical intravenous pamidronate therapy increases bone mass in children with osteogenesis imperfecta (OI), but the effect on the intrinsic material properties of bone is unknown at present." | 5.12 | Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. ( Fratzl, P; Fratzl-Zelman, N; Glorieux, FH; Klaushofer, K; Rauch, F; Roschger, P; Schöberl, T; Weber, M, 2006) |
| "To evaluate the functional abilities and the level of ambulation during pamidronate therapy in children with moderate to severe osteogenesis imperfecta." | 5.12 | Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. ( Glorieux, FH; Land, C; Montpetit, K; Rauch, F; Ruck-Gibis, J, 2006) |
| "Children with the severe forms of osteogenesis imperfecta have in several studies been treated with intravenous pamidronate, but there are only few reports of the effect of early treatment." | 5.12 | Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. ( Aström, E; Jorulf, H; Söderhäll, S, 2007) |
| "Cyclical intravenous treatment with pamidronate is of clinical benefit in children with moderate to severe osteogenesis imperfecta (OI) types I, III and IV, but there is no information on the effects of this treatment on the newly described OI type VI." | 5.12 | Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. ( Glorieux, FH; Land, C; Rauch, F; Travers, R, 2007) |
| "Pamidronate treatment has been shown to improve outcome in osteogenesis imperfecta (OI); however, factors influencing outcome are unclear." | 5.12 | Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome. ( Bajpai, A; Ghosh, M; Gupta, N; Kabra, M; Sharda, S, 2007) |
| "We evaluated the efficacy of a monthly infusion of pamidronate on the frequency of fractures, biochemical effects, and bone mineral density in children with osteogenesis imperfecta." | 5.12 | Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. ( Choi, JH; Shin, YL; Yoo, HW, 2007) |
| "Nine infants and young children with osteogenesis imperfecta (age range 1-35 months) were treated with intravenous pamidronate." | 5.11 | Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. ( DiMeglio, LA; Ford, L; McClintock, C; Peacock, M, 2004) |
| "Observations in small patient series indicate that infants with severe osteogenesis imperfecta (OI) benefit from treatment with cyclical intravenous pamidronate." | 5.11 | Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. ( Glorieux, FH; Munns, CF; Rauch, F; Travers, R, 2005) |
| "To evaluate the efficacy of pamidronate in protecting against fractures, increasing bone mineral density (BMD), and decreasing bone remodeling marker levels in children with osteogenesis imperFecta." | 5.10 | Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients. ( Giraud, F; Meunier, PJ, 2002) |
| "A prospective open study was performed to determine the efficacy and safety of pamidronate in improving bone mineralisation and reducing fracture incidence in osteogenesis imperfecta (OI)." | 5.09 | Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. ( Lee, YS; Lim, LA; Loke, KY; Low, SL, 2001) |
| "We report results of 2-5 y treatment with intravenous disodium pamidronate (APD) in three girls with severe osteogenesis imperfecta (OI)." | 5.08 | Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. ( Aström, E; Söderhäll, S, 1998) |
| "In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6." | 5.08 | Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998) |
| "The purpose of this study was to clarify the prevalence of scoliosis and determine risk factors for the development of scoliosis in young children with osteogenesis imperfecta (OI) who underwent intravenous pamidronate (PAM) therapy." | 3.91 | Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy. ( Iwasaki, M; Kaito, T; Kanayama, S; Kashii, M; Kitaoka, T; Kubota, T; Makino, T; Ozono, K; Yamamoto, T; Yoshikawa, H, 2019) |
| "To verify radiomorphometric indices and fractal dimension (FD) in dental panoramic radiographs (DPRs) of children with different types of osteogenesis imperfecta (OI) and also to verify the effect of pamidronate (PAM) treatment in such panoramic analyses." | 3.83 | Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment. ( Acevedo, AC; Apolinário, AC; Castro, LC; de Melo, NS; de Paula, AP; de Paula, LM; de Souza Figueiredo, PT; Guimarães, AT; Leite, AF; Sindeaux, R, 2016) |
| "Pamidronate treatment in children with all types of OI increased LS BMD, decreased fracture rate, and improved vertebral compression fractures." | 3.83 | Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. ( Åström, E; Grigelioniene, G; Kindmark, A; Lindahl, K; Ljunggren, Ö; Malmgren, B; Rubin, CJ; Söderhäll, S, 2016) |
| "We hypothesized that mandibular cortical width (MCW) is smaller in children with osteogenesis imperfecta (OI) than in healthy children and that pamidronate can improve the cortical mandibular thickness." | 3.81 | Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta. ( Acevedo, AC; Apolinário, AC; Castro, LC; Figueiredo, PT; Guimarães, AT; Leite, AF; Melo, NS; Paula, AP; Paula, LM, 2015) |
| "Intravenous pamidronate has been used off-label in the treatment of severe osteogenesis imperfecta (OI) for almost 20 years." | 3.80 | Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. ( Bompadre, V; Sousa, T; White, KK, 2014) |
| "The six patients, who had bone fractures either in utero or in their 1st month of life, were treated with cyclic pamidronate from a mean age of 2." | 3.80 | Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta. ( Chien, CC; Chien, YH; Hwu, WL; Lee, CT; Lee, NC; Lin, CH; Peng, SF; Tsai, WY; Tung, YC, 2014) |
| "To assess the beneficial effect of intravenous pamidronate treatment in children with osteogenesis imperfecta (OI)." | 3.80 | Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta. ( Atta, I; Ibrahim, M; Iqbal, F; Khan, YN; Lone, SW; Raza, J, 2014) |
| "Evaluate clinical outcome of early cyclic intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta (OI), commenced before three years of age." | 3.79 | Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age. ( Alcausin, MB; Ault, J; Bridge, C; Briody, J; Engelbert, RH; McQuade, M; Munns, CF; Pacey, V; Sillence, DO, 2013) |
| " To assess the role of biochemical bone markers in classification of children with osteogenesis imperfecta (OI), their possible association with vertebral compression fractures in milder forms of OI and their role in monitoring of intravenous pamidronate (APD) treatment." | 3.76 | Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta. ( Aström, E; Eksborg, S; Magnusson, P; Söderhäll, S, 2010) |
| "Cyclical intravenous treatment with pamidronate is widely used to treat osteogenesis imperfecta (OI) types I, III, and IV, which are due to dominant mutations affecting collagen type I alpha chains." | 3.75 | Intravenous pamidronate in osteogenesis imperfecta type VII. ( Cheung, MS; Glorieux, FH; Rauch, F, 2009) |
| "To assess the long-term effect of pamidronate therapy on bone mineral metabolism and bone mineral density (BMD) in children with osteogenesis imperfecta (OI) and to evaluate BMD results with respect to national standards." | 3.74 | Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. ( Bas, F; Bundak, R; Darendeliler, F; Eryilmaz, SK; Gunoz, H; Poyrazoglu, S; Saka, N; Tutunculer, F, 2008) |
| "The multidisciplinary, rational approach, which involves early surgical intramedullary fixation of fractures with subsequent rehabilitation and Pamidronate administration, is considered to provide a more effective therapy with better results and therefore better quality of life in patients with osteogenesis imperfecta." | 3.74 | [Role of an interdisciplinary approach in the healing of long bone fractures in patients with osteogenesis imperfecta]. ( Kokavec, M; Novorolský, K; Pribilincová, Z, 2008) |
| "Information on the long-term efficacy of intravenous pamidronate therapy in Asian patients with osteogenesis imperfecta (OI) is limited." | 3.74 | Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta. ( Chang, CY; Chen, MR; Chuang, CK; Lin, HY; Lin, SP, 2008) |
| "Cyclical intravenous pamidronate is a widely used symptomatic therapy in moderate to severe osteogenesis imperfecta (OI)." | 3.74 | Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. ( Cheung, M; Cornibert, S; Glorieux, FH; Rauch, F, 2007) |
| "To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI)." | 3.74 | Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. ( Aström, E; Eliasson, AC; Löwing, K; Oscarsson, KA; Söderhäll, S, 2007) |
| "Recent studies reported beneficial effect of cyclical intravenous administration of pamidronate in children and adolescents with osteogenesis imperfecta (OI)." | 3.74 | Alendronate treatment in children with osteogenesis imperfecta. ( Akcay, T; Bereket, A; Guran, T; Turan, S, 2008) |
| "To determine the effect of intravenous pamidronate on the bone mineral density of children with osteogenesis imperfecta and spastic quadriplegic cerebral palsy." | 3.73 | Bone densitometry in pediatric patients treated with pamidronate. ( Bachrach, SJ; Grissom, LE; Harcke, HT; Kecskemethy, HH; McKay, C, 2005) |
| "To study the efficacy of pamidronate in children with osteogenesis imperfecta (OI)." | 3.73 | Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. ( Arabi, A; Bensman, A; Filipe, G; Forin, V; Guigonis, V; Roux, C, 2005) |
| "Intravenous treatment with pamidronate is beneficial in children and adolescents with moderate to severe forms of osteogenesis imperfecta (OI) types I, III and IV, but there is little information on the effects of this treatment on the newly described OI type V." | 3.73 | The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V. ( Glorieux, FH; Munns, C; Rauch, F; Travers, R; Zeitlin, L, 2006) |
| "Intravenous pamidronate treatment is beneficial to children and adolescents with osteogenesis imperfecta (OI), but the effects of prolonged therapy are not well characterized." | 3.73 | Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. ( Glorieux, FH; Rauch, F; Travers, R, 2006) |
| "Four infant outcomes of pregnancies of three women, two with polyostotic fibrous dysplasia and one with osteogenesis imperfecta, all of whom were treated with iv pamidronate before conception, are reported, with biochemical, radiological, and bone density data." | 3.73 | Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. ( Chan, B; Zacharin, M, 2006) |
| "The aim of this study was to evaluate the efficacy of pamidronate in the management of osteogenesis imperfecta patients." | 3.73 | Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study. ( Basha, NE; el-Sobky, MA; Hanna, AA; Said, MH; Tarraf, YN, 2006) |
| "Results in small patient series suggest that cyclical intravenous treatment with pamidronate can lead to reshaping of compressed vertebral bodies in children and adolescents with osteogenesis imperfecta (OI), but more detailed analyses are lacking." | 3.73 | Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. ( Glorieux, FH; Land, C; Munns, CF; Rauch, F; Sahebjam, S, 2006) |
| "In recent years, bisphosphonates, primarily intravenous (iv) pamidronate, have become very widely used in children with severe osteogenesis imperfecta (OI)." | 3.73 | Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children. ( Henderson, R, 2006) |
| "Cyclical iv therapy with pamidronate improves the clinical course in children and adolescents with osteogenesis imperfecta (OI)." | 3.72 | Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. ( Glorieux, FH; Plotkin, H; Rauch, F; Travers, R; Zeitlin, L, 2003) |
| "Cyclical intravenous therapy with pamidronate improves the clinical course in children and adolescents with osteogenesis imperfecta (OI)." | 3.72 | Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. ( Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003) |
| "Treatment with pamidronate improves the clinical course in children with osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth." | 3.72 | Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. ( Glorieux, FH; Plotkin, H; Rauch, F; Zeitlin, L, 2003) |
| "To examine changes in grip force during pamidronate therapy in children and adolescents with severe osteogenesis imperfecta (OI)." | 3.72 | Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. ( Bilodeau, N; Cloutier, S; Glorieux, FH; Montpetit, K; Plotkin, H; Rabzel, M; Rauch, F, 2003) |
| "This report aims to describe the adverse respiratory events associated with the first pamidronate cycle in four infants with severe osteogenesis imperfecta (OI) who were less than 2 years of age." | 3.72 | Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. ( Glorieux, FH; Mier, RJ; Munns, CF; Rauch, F, 2004) |
| "The pregnancies of two women with osteogenesis imperfecta who received intravenous pamidronate before conception are reported." | 3.72 | Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. ( Glorieux, FH; Munns, CF; Rauch, F; Ward, L, 2004) |
| "Intravenous pamidronate is widely used to treat children with moderate to severe osteogenesis imperfecta (OI)." | 3.72 | Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. ( Fassier, F; Glorieux, FH; Munns, CF; Rauch, F; Zeitlin, L, 2004) |
| "Cyclical pamidronate infusions increase bone mass in children suffering from osteogenesis imperfecta." | 3.71 | The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. ( Glorieux, FH; Plotkin, H; Rauch, F; Travers, R, 2002) |
| ") (brittle bone disease) is primarily supportive; early introduction of cyclic intravenous pamidronate administration in children younger than 2 years of age is an innovative and promising therapeutic approach." | 3.71 | [Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report]. ( al-Jazayri, Z; Amiour, M; Desrosieres, H; Eckart, P; Guillot, M, 2001) |
| "Pamidronate seems to be useful in the treatment of patients with osteogenesis imperfecta." | 3.71 | Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. ( Escolá, J; González, E; Pavía, C; Ros, J; Valls, C; Villaronga, M, 2001) |
| "The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures." | 3.69 | Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. ( Ball, RJ; Smith, RA; Wilkinson, H; Williams, CJ, 1997) |
| "Three children with osteogenesis imperfecta, severe osteopenia, and repeated fractures were treated with cyclic infusions of aminohydroxypropylidene bisphosphonate (pamidronate) for a period ranging from 22 to 29 months." | 3.69 | Intravenous pamidronate treatment in osteogenesis imperfecta. ( Bembi, B; Bottega, M; Ceschel, S; Ciana, G; Martini, C; Parma, A; Zanatta, M, 1997) |
| "Treatment with pamidronate resulted in only a slight enhancement of mineralization." | 2.84 | Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation. ( Blouin, S; Fratzl-Zelman, N; Glorieux, FH; Klaushofer, K; Marini, JC; Rauch, F; Roschger, P, 2017) |
| "Pamidronate-treated type III/IV and oral bisphosphonate-treated type I patients showed significant increases in total-hip BMD (0." | 2.75 | Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. ( Gillen, C; Nunes, M; Shapiro, JR; Thompson, CB; Wu, Y, 2010) |
| "Pamidronate treatment led to significant increases in bone mineral density (BMD), measured by DXA, in the lumbar spine at 12 months (P = 0." | 2.71 | The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. ( Bober, M; Ernest, K; Fedarko, N; Gelman, R; McCarthy, EF; Rossiter, K; Santiago, HT; Shapiro, JR, 2003) |
| "Pamidronate treatment improves bone quality in children with mild types of OI." | 2.71 | Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004) |
| "Pamidronate treatment of severe forms of OI is an effective therapeutic modality to increase bone density, decrease fracture rate, increase mobility and improve quality of life, irrespective of the severity of the mutation or clinical phenotype." | 2.70 | Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. ( Bateman, J; Zacharin, M, 2002) |
| "Pamidronate treatment in severely affected OI patients under 3 yr of age is safe, increases BMD, and decreases fracture rate." | 2.69 | Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. ( Bishop, NJ; Glorieux, FH; Montpetit, K; Plotkin, H; Rauch, F; Ruck-Gibis, J; Travers, R, 2000) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| "Zoledronic acid has undergone international multicentric clinical trials to examine efficiency and long-term side effects including osteonecrosis of the jaw." | 2.45 | [Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta]. ( Yamashita, S, 2009) |
| "Osteogenesis Imperfecta is a heritable disorder characterized by bone fragility and low bone mass, with a wide spectrum of clinical expression." | 2.44 | Osteogenesis imperfecta. ( Glorieux, FH, 2008) |
| "Classic treatments of osteogenesis imperfecta for children and adults include rehabilitation therapy and orthopedic surgery." | 2.43 | Osteogenesis imperfecta: new treatment options. ( Chevrel, G; Cimaz, R, 2006) |
| "Osteogenesis imperfecta is characterised by low bone mineral density, bone fragility, fractures and deformity." | 1.62 | Intravenous pamidronate for treatment of osteogenesis imperfecta in Indian children. ( Goel, A; Johari, A; Shah, I; Shetty, NS, 2021) |
| " At this point, closed fractures were made using an Einhorn apparatus, and bisphosphonate dosing was continued until the experimental endpoint." | 1.56 | Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model. ( Little, DG; McDonald, MM; Mikulec, K; Morse, A; Munns, CF; Schindeler, A, 2020) |
| "We report an additional case where arachnoid cysts extend the phenotype, and that also confirms the association of intellectual disabilities with asymmetric cerebellar hypoplasia here." | 1.51 | WNT1-associated osteogenesis imperfecta with atrophic frontal lobes and arachnoid cysts. ( Carlson, BM; Dejkhamron, P; Intachai, W; Kampuansai, J; Kantaputra, PN; Petcharunpaisan, S; Sirirungruangsarn, Y; Sudasna, J; Visrutaratna, P, 2019) |
| "Pamidronate treatment significantly increased the Z score in all patients, and increases in the Z score did not correlate with the OI types, causative genes, or genotype." | 1.48 | Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta. ( Fujiwara, I; Kanno, J; Kure, S; Saito-Hakoda, A, 2018) |
| "Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI." | 1.46 | Therapy with pamidronate in children with osteogenesis imperfecta. ( Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017) |
| "Pamidronate was discontinued after 7 years of therapy, following which she sustained two further nontraumatic femur fractures, and continued to show delayed tibial osteotomy healing." | 1.43 | Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating? ( Bishop, NJ; Högler, W; Sanghrajka, A; Vasanwala, RF, 2016) |
| "Osteogenesis imperfecta is a heritable disorder of bone connective tissue." | 1.43 | Pamidronate treatment for osteogenesis imperfecta in black South Africans. ( Henderson, BD; Isaac, N; Khiba, S; Mabele, O; Mokoena, T; Nkayi, A, 2016) |
| "Pamidronate was administered in three-day cycles." | 1.42 | Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age. ( Ayoob, R; Bowden, SA; Ingraham, S; Kusumi, K; Mahan, JD, 2015) |
| "This report details the development of respiratory failure during the second infusion of pamidronate in a 3." | 1.40 | Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report. ( Olson, JA, 2014) |
| "Subsequent radiographs revealed a 14-cm abdominal aortic aneurysm eroding the vertebrae." | 1.39 | An unusual cause of spinal bone loss detected by DXA scanning. ( Davie, MW; Davies, H, 2013) |
| " Adverse events were measured by collecting calcium levels before and after infusions." | 1.38 | Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings. ( DeHaai, K; Kreikemeier, RM; Lutz, RE; Rush, ET, 2012) |
| "Pamidronate (PAM), which has to be administered as a 3-day course according to the original protocol by Glorieux, is the most frequently used therapy." | 1.37 | Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta. ( Beccard, R; Demant, A; Fricke, O; Koerber, F; Palmisano, D; Schoenau, E; Semler, O, 2011) |
| "Osteogenesis imperfecta is characterised by bone fragility leading to fracture and bone deformity, chronic bone pain and reduced mobility." | 1.36 | Characterising and treating osteogenesis imperfecta. ( Bishop, N, 2010) |
| "Pamidronate therapy has a positive impact on functional parameters including improved energy, decreased bone pain, and increased ambulation." | 1.34 | Experience with bisphosphonates in osteogenesis imperfecta. ( Glorieux, FH, 2007) |
| "Pretreatment with ibuprofen or acetaminophen appears to decrease the occurrence of adverse events from pamidronate therapy." | 1.32 | Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. ( Bates, CM; Batisky, DL; Hayes, JR; Mahan, JD; Nahata, MC; Robinson, RE, 2004) |
| "Bisphosphonates are now widely used to treat children with osteogenesis imperfecta (OI)." | 1.32 | Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. ( Arikoski, P; Bishop, NJ; Silverwood, B; Tillmann, V, 2004) |
| "To find an effective symptomatic treatment for osteogenesis imperfecta (OI)." | 1.31 | Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. ( Aström, E; Söderhäll, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.61) | 18.7374 |
| 1990's | 9 (5.52) | 18.2507 |
| 2000's | 93 (57.06) | 29.6817 |
| 2010's | 50 (30.67) | 24.3611 |
| 2020's | 10 (6.13) | 2.80 |
| Authors | Studies |
|---|---|
| Pantoja, LLQ | 1 |
| Lustosa, M | 1 |
| Yamaguti, PM | 1 |
| Rosa, LS | 1 |
| Leite, AF | 3 |
| Figueiredo, PTS | 1 |
| Castro, LC | 3 |
| Acevedo, AC | 3 |
| Wei, S | 1 |
| Yao, Y | 1 |
| Shu, M | 1 |
| Gao, L | 1 |
| Zhao, J | 1 |
| Li, T | 1 |
| Wang, Y | 1 |
| Xu, C | 1 |
| Fukahori, K | 1 |
| Nirei, J | 1 |
| Yamawaki, K | 1 |
| Nagasaki, K | 1 |
| Goyal, P | 1 |
| Gupta, S | 1 |
| Morse, A | 1 |
| McDonald, MM | 1 |
| Mikulec, K | 1 |
| Schindeler, A | 1 |
| Munns, CF | 9 |
| Little, DG | 1 |
| Malmgren, B | 2 |
| Tsilingaridis, G | 1 |
| Monsef-Johansson, N | 1 |
| Qahtani, ZHA | 1 |
| Dahllöf, G | 1 |
| Åström, E | 8 |
| Harada, D | 1 |
| Kashiwagi, H | 1 |
| Ueyama, K | 1 |
| Oriyama, K | 1 |
| Hanioka, Y | 1 |
| Sakamoto, N | 1 |
| Kondo, K | 1 |
| Kishimoto, K | 1 |
| Izui, M | 1 |
| Nagamatsu, Y | 1 |
| Yamada, H | 1 |
| Tanaka, H | 2 |
| Namba, N | 2 |
| Seino, Y | 2 |
| Celik, NB | 1 |
| Gonc, N | 2 |
| Ozon, A | 2 |
| Alikasifoglu, A | 3 |
| Rauch, F | 29 |
| Kandemir, N | 2 |
| Shah, I | 1 |
| Goel, A | 1 |
| Shetty, NS | 1 |
| Johari, A | 1 |
| Krishnan, S | 1 |
| Rughani, A | 1 |
| Tsai, A | 1 |
| Palle, S | 1 |
| Erbaş, İM | 1 |
| İlgün Gürel, D | 1 |
| Manav Kabayeğit, Z | 1 |
| Koç, A | 1 |
| Ünüvar, T | 1 |
| Abacı, A | 1 |
| Böber, E | 1 |
| Anık, A | 1 |
| Kanno, J | 1 |
| Saito-Hakoda, A | 1 |
| Kure, S | 1 |
| Fujiwara, I | 2 |
| Blouin, S | 1 |
| Fratzl-Zelman, N | 2 |
| Glorieux, FH | 35 |
| Roschger, P | 2 |
| Klaushofer, K | 2 |
| Marini, JC | 4 |
| Biggin, A | 2 |
| Marginean, O | 1 |
| Tamasanu, RC | 1 |
| Mang, N | 1 |
| Mozos, I | 1 |
| Brad, GF | 1 |
| Olvera, D | 2 |
| Stolzenfeld, R | 2 |
| Caird, MS | 2 |
| Kozloff, KM | 2 |
| Eto, S | 1 |
| Hada, S | 1 |
| Fukuhara, R | 1 |
| Nishimura, G | 1 |
| Takagi, M | 1 |
| Jain, M | 1 |
| Tam, A | 1 |
| Shapiro, JR | 4 |
| Steiner, RD | 1 |
| Smith, PA | 1 |
| Bober, MB | 1 |
| Hart, T | 1 |
| Cuthbertson, D | 1 |
| Krischer, J | 1 |
| Mullins, M | 1 |
| Bellur, S | 1 |
| Byers, PH | 1 |
| Pepin, M | 1 |
| Durigova, M | 1 |
| Lee, B | 1 |
| Sutton, VR | 1 |
| Nagamani, SCS | 1 |
| Chen, Y | 1 |
| Sebag, M | 1 |
| Powell, TI | 1 |
| Morin, SN | 1 |
| Kashii, M | 1 |
| Kanayama, S | 1 |
| Kitaoka, T | 2 |
| Makino, T | 1 |
| Kaito, T | 1 |
| Iwasaki, M | 1 |
| Kubota, T | 2 |
| Yamamoto, T | 2 |
| Ozono, K | 2 |
| Yoshikawa, H | 1 |
| Kantaputra, PN | 1 |
| Sirirungruangsarn, Y | 1 |
| Visrutaratna, P | 1 |
| Petcharunpaisan, S | 1 |
| Carlson, BM | 1 |
| Intachai, W | 1 |
| Sudasna, J | 1 |
| Kampuansai, J | 1 |
| Dejkhamron, P | 1 |
| Michałus, I | 1 |
| Nowicka, Z | 1 |
| Pietras, WA | 1 |
| Nowicka, M | 1 |
| Jakubowska-Pietkiewicz, E | 1 |
| Fisher, E | 1 |
| Nolan, B | 1 |
| Alcausin, MB | 1 |
| Briody, J | 1 |
| Pacey, V | 1 |
| Ault, J | 2 |
| McQuade, M | 1 |
| Bridge, C | 1 |
| Engelbert, RH | 1 |
| Sillence, DO | 2 |
| Sousa, T | 1 |
| Bompadre, V | 1 |
| White, KK | 1 |
| Miura, K | 2 |
| Oznono, K | 1 |
| Ngan, KK | 1 |
| Bowe, J | 1 |
| Goodger, N | 1 |
| Lin, CH | 1 |
| Chien, YH | 2 |
| Peng, SF | 1 |
| Tsai, WY | 1 |
| Tung, YC | 1 |
| Lee, CT | 1 |
| Chien, CC | 1 |
| Hwu, WL | 2 |
| Lee, NC | 1 |
| Choi, Y | 1 |
| Yi, NJ | 1 |
| Ko, JS | 1 |
| Ko, JM | 1 |
| Jin, US | 1 |
| Kim, HS | 1 |
| Lee, KH | 1 |
| Cho, TJ | 1 |
| Suh, SW | 1 |
| Yoo, T | 1 |
| Lee, KW | 1 |
| Suh, KS | 1 |
| Olson, JA | 1 |
| Atta, I | 1 |
| Iqbal, F | 1 |
| Lone, SW | 1 |
| Ibrahim, M | 1 |
| Khan, YN | 1 |
| Raza, J | 1 |
| Kusumi, K | 1 |
| Ayoob, R | 1 |
| Bowden, SA | 1 |
| Ingraham, S | 1 |
| Mahan, JD | 2 |
| Arponen, H | 1 |
| Vuorimies, I | 1 |
| Haukka, J | 1 |
| Valta, H | 1 |
| Waltimo-Sirén, J | 1 |
| Mäkitie, O | 1 |
| Apolinário, AC | 2 |
| Figueiredo, PT | 1 |
| Guimarães, AT | 2 |
| Paula, AP | 1 |
| Paula, LM | 1 |
| Melo, NS | 1 |
| Zheng, L | 1 |
| Briody, JN | 2 |
| Coorey, CP | 1 |
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Sinikumpu, JJ | 1 |
| Ojaniemi, M | 1 |
| Lehenkari, P | 1 |
| Serlo, W | 1 |
| Füeßl, HS | 1 |
| Palomo, T | 2 |
| Fassier, F | 3 |
| Ouellet, J | 1 |
| Sato, A | 1 |
| Montpetit, K | 4 |
| Andrade, MC | 1 |
| Peters, BS | 1 |
| Reis, FA | 1 |
| Carvalhaes, JT | 1 |
| Lazaretti-Castro, M | 2 |
| Zyma, AM | 1 |
| Guk, YM | 1 |
| Magomedov, OM | 1 |
| Gayko, OG | 1 |
| Kincha-Polishchuk, TA | 1 |
| Vasanwala, RF | 1 |
| Sanghrajka, A | 1 |
| Bishop, NJ | 6 |
| Högler, W | 1 |
| Sindeaux, R | 1 |
| de Souza Figueiredo, PT | 1 |
| de Paula, AP | 1 |
| de Paula, LM | 1 |
| de Melo, NS | 1 |
| Lindahl, K | 1 |
| Kindmark, A | 1 |
| Rubin, CJ | 1 |
| Grigelioniene, G | 1 |
| Söderhäll, S | 7 |
| Ljunggren, Ö | 1 |
| Henderson, BD | 1 |
| Isaac, N | 1 |
| Mabele, O | 1 |
| Khiba, S | 1 |
| Nkayi, A | 1 |
| Mokoena, T | 1 |
| Poyrazoglu, S | 1 |
| Gunoz, H | 1 |
| Darendeliler, F | 1 |
| Bas, F | 1 |
| Tutunculer, F | 1 |
| Eryilmaz, SK | 1 |
| Bundak, R | 1 |
| Saka, N | 1 |
| Kokavec, M | 1 |
| Novorolský, K | 1 |
| Pribilincová, Z | 1 |
| Vinson, EN | 1 |
| Rao, SH | 1 |
| Evans, KD | 1 |
| Oberbauer, AM | 1 |
| Martin, RB | 1 |
| Alharbi, M | 1 |
| Pinto, G | 1 |
| Finidori, G | 1 |
| Souberbielle, JC | 1 |
| Guillou, F | 1 |
| Gaubicher, S | 1 |
| Le Merrer, M | 1 |
| Polak, M | 1 |
| Cheung, MS | 3 |
| Andiran, N | 2 |
| Alanay, Y | 1 |
| Yordam, N | 2 |
| Lin, HY | 1 |
| Lin, SP | 2 |
| Chuang, CK | 1 |
| Chen, MR | 1 |
| Chang, CY | 1 |
| Yamashita, S | 2 |
| Brown, JJ | 1 |
| Zacharin, MR | 1 |
| Hasegawa, K | 1 |
| Inoue, M | 1 |
| Morishima, T | 1 |
| Gandon-Laloum, S | 1 |
| Namazi, H | 1 |
| Santos, C | 1 |
| Arnal, C | 1 |
| Bhadada, SK | 1 |
| Santosh, R | 1 |
| Bhansali, A | 1 |
| Upreti, V | 1 |
| Dutta, P | 1 |
| Thompson, CB | 1 |
| Wu, Y | 1 |
| Nunes, M | 1 |
| Gillen, C | 1 |
| Magnusson, P | 1 |
| Eksborg, S | 1 |
| Bishop, N | 1 |
| Arundel, P | 1 |
| Offiah, A | 1 |
| Heino, TJ | 1 |
| Laurencikas, E | 1 |
| Sävendahl, L | 1 |
| Ohata, Y | 1 |
| Fujiwara, M | 1 |
| Hirai, H | 1 |
| Kaur, S | 1 |
| Kulkarni, KP | 1 |
| Kochar, IS | 1 |
| Narasimhan, R | 1 |
| Sarraf, KM | 1 |
| Semler, O | 1 |
| Beccard, R | 1 |
| Palmisano, D | 1 |
| Demant, A | 1 |
| Fricke, O | 1 |
| Schoenau, E | 1 |
| Koerber, F | 1 |
| Davies, H | 1 |
| Davie, MW | 1 |
| Chen, CP | 1 |
| Su, YN | 1 |
| Huang, JP | 1 |
| Chern, SR | 1 |
| Su, JW | 1 |
| Wang, W | 1 |
| Barros, ER | 1 |
| Saraiva, GL | 1 |
| de Oliveira, TP | 1 |
| Rush, ET | 1 |
| DeHaai, K | 1 |
| Kreikemeier, RM | 1 |
| Lutz, RE | 1 |
| Lindsay, R | 1 |
| Travers, R | 9 |
| Plotkin, H | 7 |
| Banerjee, I | 1 |
| Shortland, GJ | 1 |
| Evans, WD | 1 |
| Gregory, JW | 2 |
| McCarthy, EF | 1 |
| Rossiter, K | 1 |
| Ernest, K | 1 |
| Gelman, R | 1 |
| Fedarko, N | 1 |
| Santiago, HT | 1 |
| Bober, M | 1 |
| Giraud, F | 1 |
| Meunier, PJ | 1 |
| Zeitlin, L | 6 |
| Falk, MJ | 1 |
| Heeger, S | 1 |
| Lynch, KA | 1 |
| DeCaro, KR | 1 |
| Bohach, D | 1 |
| Gibson, KS | 1 |
| Warman, ML | 1 |
| Langman, CB | 1 |
| Chu, SY | 1 |
| Hsu, CC | 1 |
| Grissom, LE | 2 |
| Harcke, HT | 2 |
| Bilodeau, N | 1 |
| Cloutier, S | 1 |
| Rabzel, M | 1 |
| Davies, JH | 1 |
| Robinson, RE | 1 |
| Nahata, MC | 1 |
| Hayes, JR | 1 |
| Batisky, DL | 1 |
| Bates, CM | 1 |
| Arikoski, P | 1 |
| Silverwood, B | 2 |
| Tillmann, V | 1 |
| Munns, C | 3 |
| Mier, RJ | 1 |
| Ward, L | 1 |
| DiMeglio, LA | 3 |
| Ford, L | 2 |
| McClintock, C | 2 |
| Peacock, M | 3 |
| Zacharin, M | 3 |
| Kanumakala, S | 1 |
| Bin-Abbas, BS | 1 |
| Al-Ashwal, AA | 1 |
| Al-Zayed, ZS | 1 |
| Sakati, NA | 1 |
| Popko, J | 1 |
| Galicka, A | 1 |
| Wołczyński, S | 1 |
| Zalewski, W | 1 |
| Konstantynowicz, J | 1 |
| Kecskemethy, HH | 1 |
| Bachrach, SJ | 1 |
| McKay, C | 1 |
| Fleming, F | 1 |
| Woodhead, HJ | 1 |
| Hall, J | 1 |
| Cowell, CT | 1 |
| Kozlowski, K | 1 |
| Letocha, AD | 1 |
| Cintas, HL | 1 |
| Troendle, JF | 1 |
| Reynolds, JC | 1 |
| Cann, CE | 1 |
| Chernoff, EJ | 1 |
| Hill, SC | 1 |
| Gerber, LH | 1 |
| Forin, V | 2 |
| Arabi, A | 1 |
| Guigonis, V | 1 |
| Filipe, G | 1 |
| Bensman, A | 1 |
| Roux, C | 1 |
| Srinivasan, R | 1 |
| Amarasena, S | 1 |
| Lekamwasam, S | 1 |
| Jayawardena, P | 1 |
| Land, C | 5 |
| Vallo, A | 1 |
| Rodriguez-Leyva, F | 1 |
| Rodríguez Soriano, J | 1 |
| Boot, AM | 1 |
| de Coo, RF | 1 |
| Pals, G | 1 |
| de Muinck Keizer-Schrama, SM | 1 |
| Chan, B | 1 |
| Chigladze, TT | 1 |
| Zhvaniia, MA | 1 |
| Bekua, MV | 1 |
| el-Sobky, MA | 1 |
| Hanna, AA | 1 |
| Basha, NE | 1 |
| Tarraf, YN | 1 |
| Said, MH | 1 |
| Weber, M | 1 |
| Schöberl, T | 1 |
| Fratzl, P | 1 |
| Ruck-Gibis, J | 2 |
| Sahebjam, S | 1 |
| Henderson, R | 1 |
| Chevrel, G | 1 |
| Cimaz, R | 1 |
| Di Iorgi, N | 1 |
| Maghnie, M | 1 |
| Jorulf, H | 1 |
| Cornibert, S | 1 |
| Cheung, M | 1 |
| Bajpai, A | 1 |
| Kabra, M | 1 |
| Gupta, N | 1 |
| Sharda, S | 1 |
| Ghosh, M | 1 |
| Papapoulos, SE | 1 |
| Cremers, SC | 1 |
| Choi, JH | 1 |
| Shin, YL | 1 |
| Yoo, HW | 1 |
| Löwing, K | 1 |
| Oscarsson, KA | 1 |
| Eliasson, AC | 1 |
| Onwuneme, C | 1 |
| Abdalla, K | 1 |
| Cassidy, N | 1 |
| Hensey, O | 1 |
| Ryan, S | 1 |
| Senthilnathan, S | 1 |
| Walker, E | 1 |
| Cabral de Menezes Filho, H | 1 |
| Rodrigues, JM | 1 |
| Radonsky, V | 1 |
| Della Manna, T | 1 |
| Kuperman, H | 1 |
| Steinmetz, L | 1 |
| Dichtchekenian, V | 1 |
| Damiani, D | 2 |
| Setian, N | 1 |
| Akcay, T | 1 |
| Turan, S | 1 |
| Guran, T | 1 |
| Bereket, A | 1 |
| Young, SD | 1 |
| Nelson, CL | 1 |
| Steinberg, ME | 1 |
| Williams, CJ | 1 |
| Smith, RA | 1 |
| Ball, RJ | 1 |
| Wilkinson, H | 1 |
| Bembi, B | 1 |
| Parma, A | 1 |
| Bottega, M | 1 |
| Ceschel, S | 1 |
| Zanatta, M | 1 |
| Martini, C | 1 |
| Ciana, G | 1 |
| Ogawa, E | 1 |
| Igarashi, Y | 1 |
| Ohba, M | 1 |
| Asanuma, A | 1 |
| Kodama, H | 1 |
| Kubota, K | 1 |
| Abe, T | 1 |
| Devogelaer, JP | 2 |
| Nagant de Deuxchaisnes, C | 2 |
| Chabot, G | 1 |
| Lanoue, G | 1 |
| Guillot, M | 1 |
| Eckart, P | 1 |
| Desrosieres, H | 1 |
| Amiour, M | 1 |
| al-Jazayri, Z | 1 |
| González, E | 1 |
| Pavía, C | 1 |
| Ros, J | 1 |
| Villaronga, M | 1 |
| Valls, C | 1 |
| Escolá, J | 1 |
| Lee, YS | 1 |
| Low, SL | 1 |
| Lim, LA | 1 |
| Loke, KY | 1 |
| Bateman, J | 1 |
| Laroche, M | 1 |
| Dromer, C | 1 |
| Jacquemier, JM | 1 |
| Mazières, B | 1 |
| Arlet, J | 1 |
| Malghem, J | 1 |
| Maldague, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Intraoperative Use of Tranexamic Acid in Reducing Blood Loss During Telescoping Nail Application in Osteogenesis Imperfecta - Randomized Control Trials[NCT05321199] | 20 participants (Actual) | Interventional | 2022-05-01 | Completed | |||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta[NCT01417091] | Phase 2 | 10 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Molecular Genetic Study of Suspected Cases of Osteogenesis Imperfecta Attending Assiut University Children Hospital[NCT03169192] | 40 participants (Anticipated) | Observational | 2017-06-01 | Not yet recruiting | |||
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids[NCT01197300] | Phase 3 | 25 participants (Actual) | Interventional | 2010-10-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Vertebral morphometry (or concave index) was calculated using the average ratio between mid-height and posterior height from L1 to L4 and performed by a central reader. A new morphometric vertebral fractures during the 12 month Extension Period was defined as a morphometric vertebral fracture present at Month 24 X-ray which was not present at the Extension Baseline (Baseline 2). (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) |
|---|---|
| Core Treatment Zoledronic Acid | 1 |
| Core Treatment: Placebo | 1 |
New vertebral fractures are defined as fractures of Genant grade 1 or higher that occur at lumbar or thoracic spine from first extension dose infusion to the end of the study in a previously normal vertebra. (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) |
|---|---|
| Core Treatment Zoledronic Acid | 1 |
| Core Treatment: Placebo | 1 |
Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids through the monitoring of relevant clinical and laboratory safety parameters. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) through Month 24 (Visit 15/Final Extension Visit)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| On-treatment Adverse Events (AEs) | On-treatment Serious Adverse Events (SAEs) | On-treatment Deaths | |
| Core Treatment Zoledronic Acid | 7 | 3 | 0 |
| Core Treatment: Placebo | 12 | 0 | 0 |
Left postero-anterior (PA) hand/wrist X-ray were taken at the final visit of Core study and at Visit 15/EOS (Month 24) to assess bone age. The change in 2nd metacarpal cortical width at Month 24 relative to the respective Baseline was calculated. If a fracture of the left upper extremity precluded radiographic imaging, (or precluded this X-ray in the Core study) then the right hand was evaluated for this purpose. In this case, an image of the right hand was carried out at both Visit 8 and at Visit 15/EOS (Month 24). The information was used in the assessment of bone density. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) and Baseline 2 (Visit 9 of the Extension Study) through Month 24 (Visit 15/Final Extension Visit)
| Intervention | millimeter (mm) (Least Squares Mean) | |
|---|---|---|
| 2nd metacarpal cortical width change from BL1 | 2nd metacarpal cortical width change from BL2 | |
| Core Treatment Zoledronic Acid | -0.04 | -0.09 |
| Core Treatment: Placebo | -0.03 | 0.02 |
Bone specific alkaline phosphatase (BSAP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nanogram per milliliter (ng/mL) (Least Squares Mean) | |
|---|---|---|
| BSAP Change at Month 18 | BSAP Change at Month 24 | |
| Core Treatment Zoledronic Acid | -13.716 | -9.675 |
| Core Treatment: Placebo | 3.975 | -6.013 |
Lumbar Spine Bone Mineral Content (BMC) was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | gram (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine BMC Change at Month 18 | Lumbar Spine BMC Change at Month 24 | |
| Core Treatment Zoledronic Acid | 12.293 | 15.845 |
| Core Treatment: Placebo | 9.933 | 14.666 |
Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | Z-score (Least Squares Mean) | |
|---|---|---|
| Lumbar Spine BMD Z-score Change at Month 18 | Lumbar Spine BMD Z-score Change at Month 24 | |
| Core Treatment Zoledronic Acid | -40.648 | -46.161 |
| Core Treatment: Placebo | -44.348 | -67.913 |
Serum Cross linked N-telopeptide (NTX) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nmol BCE/L (Least Squares Mean) | |
|---|---|---|
| Serum NTX Change at Month 18 | Serum NTX Change at Month 24 | |
| Core Treatment Zoledronic Acid | -17.577 | -17.450 |
| Core Treatment: Placebo | -12.916 | -14.891 |
Serum Procollagen type 1 amino-terminal propeptide (P1NP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | nanogram per milliliter (ng/mL) (Least Squares Mean) | |
|---|---|---|
| Serum P1NP Change at Month 18 | Serum P1NP Change at Month 24 | |
| Core Treatment Zoledronic Acid | -169.837 | -228.068 |
| Core Treatment: Placebo | -22.157 | -95.631 |
Serum Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | U/L (Least Squares Mean) | |
|---|---|---|
| Serum TRAP-5b Change at Month 18 | Serum TRAP-5b Change at Month 24 | |
| Core Treatment Zoledronic Acid | -2.661 | -2.670 |
| Core Treatment: Placebo | -1.179 | -2.260 |
Total body BMC were determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)
| Intervention | gram (Least Squares Mean) | |
|---|---|---|
| Total body BMC Change at Month 18 | Total body BMC Change at Month 24 | |
| Core Treatment Zoledronic Acid | 387.721 | 496.997 |
| Core Treatment: Placebo | 266.592 | 431.323 |
Pain was evaluated at each visit (at office and telephone visit) at the final visit of the Core study and first visit of the Extension study (Visit 9), Visits 11 (Month 15), 12 (Month 18), 14 (Month 21) and 15 (Month 24) using the Faces Pain Scale-Revised (FPS-R). Children were selecting the face that best fits their pain. The pain score ranged from 0 (No Pain) to 10 (Very Much Pain). The reduction in pain from Core baseline by visit was evaluated based on whether or not patients had a decrease in their FPS-R from baseline. If pain remained the same or worsened from baseline a patient was classified as '0' and if the pain scale decreased then the patient was classified as '1'. (NCT01197300)
Timeframe: Month 15, Month 18, Month 21, Month 24
| Intervention | Percentage of Patients (Number) | |||
|---|---|---|---|---|
| Reduction in Pain at Month 15 | Reduction in Pain at Month 18 | Reduction in Pain at Month 21 | Reduction in Pain at Month 24 | |
| Core Treatment Zoledronic Acid | 55.6 | 30.0 | 30.0 | 30.0 |
| Core Treatment: Placebo | 46.2 | 50.0 | 50.0 | 38.5 |
13 reviews available for pamidronate and Brittle Bone Disease
| Article | Year |
|---|---|
Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Imid | 2017 |
[Clinical condition and therapy of bone diseases].
Topics: Achondroplasia; Alkaline Phosphatase; Animals; Bone and Bones; Bone Density Conservation Agents; Col | 2013 |
The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review.
Topics: Administration, Intravenous; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conser | 2013 |
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review.
Topics: Child; Child, Preschool; Diphosphonates; Fractures, Bone; Humans; Immobilization; Infant; Infant, Ne | 2015 |
[Bisphosphonates and other new therapeutic agents for the treatmednt of osteogenesis imperfecta].
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2009 |
[Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Child; Child, Preschool; Diphos | 2010 |
Modern approach to children with osteogenesis imperfecta.
Topics: Biopsy, Needle; Bone Density; Child; Child, Preschool; Combined Modality Therapy; Diphosphonates; Fe | 2003 |
Osteogenesis imperfecta: new treatment options.
Topics: Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Clinical Trials as Topic; Diphosphonates; | 2006 |
Treatment of osteogenesis imperfecta: who, why, what?
Topics: Age Factors; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Child, Preschool; D | 2007 |
Osteogenesis imperfecta.
Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Humans; Ilium; Osteogenes | 2008 |
Osteogenesis Imperfecta: update on presentation and management.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Osteogenesis Imperfecta; Pamidronate | 2008 |
Osteogenesis imperfecta: care and management.
Topics: Child; Child, Preschool; Combined Modality Therapy; Diphosphonates; Female; Hospitals, Pediatric; Hu | 2001 |
37 trials available for pamidronate and Brittle Bone Disease
| Article | Year |
|---|---|
Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Drug Administr | 2020 |
Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
Topics: Adolescent; Bone Density; Calcinosis; Cancellous Bone; Child; Child, Preschool; Collagen Type I; Col | 2017 |
The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta.
Topics: Administration, Intravenous; Bone Density; Child; Child, Preschool; Diphosphonates; Drug Substitutio | 2015 |
Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
Topics: Administration, Intravenous; Adolescent; Bone Density; Bone Density Conservation Agents; Child; Chil | 2016 |
Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Topics: Adolescent; Anthropometry; Bone Density Conservation Agents; Child; Child, Preschool; Densitometry; | 2009 |
Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child Development; Child, Prescho | 2009 |
Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Stu | 2010 |
Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients.
Topics: Body Constitution; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Development; | 2011 |
Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta.
Topics: Adolescent; Child; Child, Preschool; Diphosphonates; Female; Fibroblast Growth Factor-23; Fibroblast | 2011 |
Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; | 2012 |
The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Topics: Adult; Bone and Bones; Bone Density; Bone Remodeling; Diphosphonates; Female; Humans; Infusions, Int | 2003 |
Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
Topics: Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Fem | 2002 |
Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Topics: Adolescent; Age Factors; Bone Density; Child; Child, Preschool; Diphosphonates; Disability Evaluatio | 2003 |
Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
Topics: Alkaline Phosphatase; Amino Acids; Anti-Inflammatory Agents; Bone Density; Calcium; Child, Preschool | 2004 |
Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Body Height; Body Weight; Bone and Bones; | 2004 |
A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
Topics: Administration, Oral; Adolescent; Age Factors; Alendronate; Anti-Inflammatory Agents; Bone Density; | 2005 |
Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Topics: Adolescent; Anti-Inflammatory Agents; Body Height; Bone and Bones; Bone Density; Bone Development; C | 2005 |
Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.
Topics: Bone and Bones; Diphosphonates; Female; Humans; Ilium; Infant; Injections, Intravenous; Lumbar Verte | 2005 |
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Ch | 2006 |
Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Topics: Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone | 2006 |
Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
Topics: Bone Density Conservation Agents; Bone Development; Bone Remodeling; Child; Child, Preschool; Cohort | 2006 |
Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Topics: Adolescent; Adult; Alkaline Phosphatase; Body Weights and Measures; Bone Density; Bone Density Conse | 2006 |
[Influence of bisphosphonate treatment on the radiological features of osteogenesis imperfecta in children].
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Human | 2006 |
Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Elasticity; Female; Humans; Male; | 2006 |
Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
Topics: Activities of Daily Living; Adolescent; Analysis of Variance; Bone Density Conservation Agents; Chil | 2006 |
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Body Height; Body Weight; Bone Density; Bone Density Conservation Agents; Ch | 2007 |
Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcium; Child; Ch | 2007 |
Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
Topics: Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Humans; Osteogenesis Imperfecta; | 2007 |
Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; Diphosphonates; Female; | 2007 |
Two doses of pamidronate in infants with osteogenesis imperfecta.
Topics: Bone Density; Bone Density Conservation Agents; Bone Remodeling; Child, Preschool; Diphosphonates; D | 2008 |
Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Child; Child, Pres | 2008 |
Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Activities of Daily Living; Adolescent; Adult; Alkaline Phosphatase; Bone De | 1998 |
Intravenous pamidronate treatment in osteogenesis imperfecta.
Topics: Antineoplastic Agents; Child; Child, Preschool; Diphosphonates; Female; Humans; Injections, Intraven | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C | 1998 |
Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
Topics: Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Infant; Lumbar Vertebrae; Male; Osteo | 2000 |
Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Calcificat | 2001 |
Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Topics: Adolescent; Age Factors; Bone Density; Bone Remodeling; Calcium; Child; Child, Preschool; Collagen; | 2002 |
113 other studies available for pamidronate and Brittle Bone Disease
| Article | Year |
|---|---|
Pamidronate Therapy Increases Trabecular Bone Complexity of Mandibular Condyles in Individuals with Osteogenesis Imperfecta.
Topics: Adolescent; Bone Density; Cancellous Bone; Child; Diphosphonates; Female; Humans; Male; Mandibular C | 2022 |
Genotype-Phenotype Relationship and Follow-up Analysis of a Chinese Cohort With Osteogenesis Imperfecta.
Topics: China; Collagen Type I; Follow-Up Studies; Genotype; Humans; Mutation; Osteogenesis Imperfecta; Pami | 2022 |
Cyclic intravenous pamidronate for an infant with osteogenesis imperfecta type II.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Infant; Infant, Newb | 2023 |
Young Female With Pain in the Left Leg.
Topics: Accidental Falls; Bone Density Conservation Agents; Child; Female; Femur; Fibula; Humans; Leg; Leg B | 2019 |
Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bony Callus; Disease Model | 2020 |
Bisphosphonate Therapy and Tooth Development in Children and Adolescents with Osteogenesis Imperfecta.
Topics: Adolescent; Case-Control Studies; Child; Diphosphonates; Female; Humans; Male; Osteogenesis Imperfec | 2020 |
Treatment response to long term antiresorptive therapy in osteogenesis imperfecta type VI: does genotype matter?
Topics: Bone Density; Bone Density Conservation Agents; Child; Humans; Infant; Male; Osteogenesis Imperfecta | 2020 |
Intravenous pamidronate for treatment of osteogenesis imperfecta in Indian children.
Topics: Administration, Intravenous; Child; Child, Preschool; Female; Humans; India; Male; Osteogenesis Impe | 2021 |
Novel compound heterozygous variants in the
Topics: Bone Density Conservation Agents; Dwarfism; Exome Sequencing; Female; Heterozygote; Humans; Infant; | 2021 |
Clinical, genetic characteristics and treatment outcomes of children and adolescents with osteogenesis imperfecta: a two-center experience.
Topics: Adolescent; Child; Child, Preschool; Collagen Type I; Connective Tissue Diseases; Female; Fractures, | 2022 |
Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Child; Child, Preschool; Collagen Type I; Diphosphonates; DNA Mutational A | 2018 |
Therapy with pamidronate in children with osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Child; Child, Pres | 2017 |
Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies; Biomechanical Phenomena; Cancellous Bone; | 2018 |
Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Humans; Infant; Infa | 2018 |
Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study.
Topics: Adolescent; Adult; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Diphosphonate | 2019 |
Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Humans; Middle Aged; Mu | 2018 |
Development of scoliosis in young children with osteogenesis imperfecta undergoing intravenous bisphosphonate therapy.
Topics: Administration, Intravenous; Adolescent; Child; Child, Preschool; Diphosphonates; Female; Humans; Ma | 2019 |
WNT1-associated osteogenesis imperfecta with atrophic frontal lobes and arachnoid cysts.
Topics: Arachnoid Cysts; Central Nervous System; Cerebellum; Developmental Disabilities; Frontal Lobe; Human | 2019 |
Pamidronate administration may result in anaemia in children with osteogenesis imperfecta.
Topics: Adolescent; Anemia; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Humans; Infant; I | 2019 |
Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta.
Topics: Animals; Bone Density; Disease Models, Animal; Female; Humans; Lactation; Mice; Osteogenesis; Osteog | 2019 |
Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Topics: Bone Density; Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Female; Fractures, | 2013 |
Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
Topics: Absorptiometry, Photon; Adolescent; Bone Density Conservation Agents; Bone Remodeling; Child; Child, | 2014 |
Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.
Topics: Bone Density; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Female; Fractur | 2014 |
Living donor liver transplantation for an infant with osteogenesis imperfecta and intrahepatic cholestasis: report of a case.
Topics: Bone Density; Bone Density Conservation Agents; Cholestasis, Intrahepatic; Diphosphonates; Fractures | 2014 |
Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report.
Topics: Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Humans; Infusions, Intravenous; | 2014 |
Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Administration, Intravenous; Administration, Oral; Adolescent; Bone Density; | 2014 |
Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
Topics: Administration, Intravenous; Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Chil | 2015 |
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administ | 2015 |
Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Administration, Intravenous; Adolescent; Age Factors; Bone Density; Bone Den | 2015 |
[Zebra bones after bisphosphonate treatment].
Topics: Bone Density; Child; Diphosphonates; Drug Administration Schedule; Humans; Male; Osteoclasts; Osteog | 2015 |
Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Topics: Absorptiometry, Photon; Adolescent; Anthropometry; Bone and Bones; Bone Density; Bone Density Conser | 2015 |
[PREPARATIONS OF PAMIDRONOVIC ACID IN COMPLEX TREATMENT ON OSTEOGENESIS IMPERFECTA].
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Di | 2015 |
Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating?
Topics: Adolescent; Child; Child, Preschool; Diphosphonates; Female; Femoral Fractures; Humans; Osteogenesis | 2016 |
Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Resorption; Child; Child, Preschool | 2016 |
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Topics: Body Height; Bone Density; Child; Child, Preschool; Collagen Type I; Diphosphonates; DNA Mutational | 2016 |
Pamidronate treatment for osteogenesis imperfecta in black South Africans.
Topics: Adolescent; Attitude to Health; Black People; Bone Density Conservation Agents; Child; Child, Presch | 2016 |
Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Child; Child, | 2008 |
[Role of an interdisciplinary approach in the healing of long bone fractures in patients with osteogenesis imperfecta].
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Femor | 2008 |
Clinical image: Pamidronate "zebra" lines.
Topics: Bone Density Conservation Agents; Child; Diphosphonates; Humans; Knee; Male; Osteogenesis Imperfecta | 2008 |
Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.
Topics: Animals; Bone Development; Bone Remodeling; Diphosphonates; Disease Models, Animal; Dose-Response Re | 2008 |
Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
Topics: Absorptiometry, Photon; Amino Acids; Bone Density; Bone Density Conservation Agents; Child; Child, P | 2009 |
Cyclic pamidronate treatment in Bruck syndrome: proposal of a new modality of treatment.
Topics: Administration, Oral; Bone Density Conservation Agents; Calcitonin; Calcium Compounds; Clubfoot; Con | 2008 |
Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta.
Topics: Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosph | 2008 |
Intravenous pamidronate in osteogenesis imperfecta type VII.
Topics: Adolescent; Blood Chemical Analysis; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2009 |
Growth of infants with osteogenesis imperfecta treated with bisphosphonate.
Topics: Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Fractures, Bone; Growth; Humans; | 2009 |
[Biphosphonates and osteogenesis imperfecta in children].
Topics: Absorptiometry, Photon; Administration, Oral; Bone Density; Bone Density Conservation Agents; Child; | 2009 |
Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome: a novel molecular mechanism.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Humans; Osteogenesis Imperfecta; Pamidron | 2009 |
[Stop in bone remodeling in imperfect osteogenesis].
Topics: Anti-Inflammatory Agents; Bone Density Conservation Agents; Bone Remodeling; Child; Diphosphonates; | 2010 |
Osteogenesis imperfecta.
Topics: Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosph | 2009 |
Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
Topics: Adolescent; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation A | 2010 |
Characterising and treating osteogenesis imperfecta.
Topics: Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Diagnosis, Differential; Diphosph | 2010 |
Evolution of the radiographic appearance of the metaphyses over the first year of life in type V osteogenesis imperfecta: clues to pathogenesis.
Topics: Arm Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cranial Fontanelles; Diphosph | 2011 |
Management of lower limb deformities in children with osteogenesis imperfecta.
Topics: Calcium; Child; Diphosphonates; Fractures, Bone; Humans; Lower Extremity; Male; Osteogenesis Imperfe | 2011 |
Images in clinical medicine. Radiographic zebra lines from cyclical pamidronate therapy.
Topics: Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Humans; Male; Osteogenesis Im | 2011 |
Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2011 |
An unusual cause of spinal bone loss detected by DXA scanning.
Topics: Absorptiometry, Photon; Aged; Aortic Aneurysm, Abdominal; Bone Density; Bone Density Conservation Ag | 2013 |
Uncomplicated vaginal delivery in two consecutive pregnancies carried to term in a woman with osteogenesis imperfecta type I and bisphosphonate treatment before conception.
Topics: Adult; Bone Density Conservation Agents; Delivery, Obstetric; Diphosphonates; Female; Humans; Infant | 2012 |
Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
Topics: Adolescent; Ambulatory Care; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Cost | 2012 |
Modeling the benefits of pamidronate in children with osteogenesis imperfecta.
Topics: Bone Development; Child; Diphosphonates; Humans; Osteogenesis Imperfecta; Pamidronate | 2002 |
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Bone Resorption; Child; | 2002 |
Osteogenesis imperfecta and intravenous pamidronate.
Topics: Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; Diphosphonates; Drug Administration | 2002 |
Improvement of bone in patients with osteogenesis imperfecta treated with pamidronate-lessons from biochemistry.
Topics: Bone and Bones; Diphosphonates; Humans; Osteogenesis Imperfecta; Pamidronate; Parathyroid Hormone | 2003 |
Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.
Topics: Adolescent; Bone and Bones; Calcium; Child; Child, Preschool; Collagen Type I; Creatinine; Diphospho | 2003 |
Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant.
Topics: Diphosphonates; Female; Humans; Infant, Newborn; Leg Bones; Osteogenesis Imperfecta; Pamidronate; Ra | 2002 |
Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
Topics: Adolescent; Bone and Bones; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Humans; I | 2003 |
Radiographic features of bisphosphonate therapy in pediatric patients.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Development; Bone Diseases, Metabolic; Cerebral Palsy | 2003 |
Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Topics: Adolescent; Aging; Body Height; Body Weight; Bone and Bones; Bone Density; Child; Child Development; | 2003 |
Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Diphosphonates; Female; Hand Strength; H | 2003 |
Radiographic long bone appearance in a child administered cyclical pamidronate.
Topics: Anti-Inflammatory Agents; Bone Density; Child; Diphosphonates; Female; Humans; Osteogenesis Imperfec | 2003 |
Bisphosphonates in children with bone diseases.
Topics: Animals; Bone Density; Child; Diphosphonates; Humans; Knee Joint; Male; Osteogenesis Imperfecta; Ost | 2003 |
Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
Topics: Abdominal Pain; Acetaminophen; Adolescent; Child; Child, Preschool; Diphosphonates; Female; Hospital | 2004 |
Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
Topics: Absorptiometry, Photon; Adolescent; Biomarkers; Bone and Bones; Child; Child, Preschool; Diphosphona | 2004 |
Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis.
Topics: Bone Remodeling; Child; Diphosphonates; Female; Humans; Ilium; Osteoclasts; Osteogenesis Imperfecta; | 2004 |
Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta.
Topics: Diphosphonates; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Male; Osteogenesis Imperfec | 2004 |
Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
Topics: Adult; Anti-Inflammatory Agents; Clubfoot; Diphosphonates; Female; Humans; Hypocalcemia; Infant; Inj | 2004 |
Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
Topics: Absorptiometry, Photon; Adolescent; Anti-Inflammatory Agents; Bone and Bones; Bone Density; Bone Rem | 2004 |
Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Child; Child, Preschool; Diphosphona | 2004 |
[Osteogenesis imperfecta as an interdisciplinary medical problem].
Topics: Absorptiometry, Photon; Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Collagen; Dip | 2004 |
Bone densitometry in pediatric patients treated with pamidronate.
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone Density; Cerebral Palsy; Child; Child, Preschool; Di | 2005 |
Cyclic bisphosphonate therapy in osteogenesis imperfecta type V.
Topics: Anti-Inflammatory Agents; Child; Diphosphonates; Female; Humans; Osteogenesis Imperfecta; Pamidronat | 2005 |
[Osteogenesis imperfecta and bisphosphonates].
Topics: Adolescent; Child; Child, Preschool; Diphosphonates; Female; Humans; Infant; Male; Osteogenesis Impe | 2005 |
Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Topics: Adolescent; Alkaline Phosphatase; Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; C | 2005 |
The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcium; Canada; C | 2006 |
Pamidronate lines.
Topics: Antineoplastic Agents; Bone Density; Child, Preschool; Diphosphonates; Femur; Humans; Male; Osteogen | 2005 |
Cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Bone Density; Child; Child, Preschool; Cohort Studies; Diphosphonates; Dose- | 2005 |
Osteogenesis imperfecta, current and future medical treatment.
Topics: Age Factors; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relatio | 2005 |
Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
Topics: Adolescent; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Child; Child, Pr | 2006 |
Muscle weakness as presenting symptom of osteogenesis imperfecta.
Topics: Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Electromyography; Electrophoresi | 2006 |
Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases.
Topics: Adult; Bone and Bones; Calcium; Diphosphonates; Female; Fetus; Fibrous Dysplasia, Polyostotic; Human | 2006 |
Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: a comparative study.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Combined Modali | 2006 |
Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Topics: Absorptiometry, Photon; Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; | 2006 |
Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy; Child; Chi | 2006 |
Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome.
Topics: Activities of Daily Living; Bone Density Conservation Agents; Diphosphonates; Humans; Infusions, Int | 2006 |
Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
Topics: Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Bone Development; Child; Child, P | 2007 |
Experience with bisphosphonates in osteogenesis imperfecta.
Topics: Bone Density; Bone Density Conservation Agents; Bone Development; Diphosphonates; Dose-Response Rela | 2007 |
Prolonged bisphosphonate release after treatment in children.
Topics: Adolescent; Arthritis, Juvenile; Bone Density Conservation Agents; Child; Diphosphonates; Half-Life; | 2007 |
Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2007 |
Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
Topics: Adolescent; Bone Density Conservation Agents; Child, Preschool; Diphosphonates; Drug Administration | 2007 |
Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
Topics: Alkaline Phosphatase; Bone Density Conservation Agents; Bone Remodeling; Child; Child, Preschool; Di | 2007 |
Metaphyseal sclerosis associated with bisphosphonate therapy.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Huma | 2007 |
Alendronate treatment in children with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Diphos | 2008 |
Transient osteoporosis of the hip in association with osteogenesis imperfecta: two cases, one complicated by a femoral neck fracture.
Topics: Aged; Anti-Inflammatory Agents; Diphosphonates; Femoral Neck Fractures; Fracture Fixation, Internal; | 2008 |
Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.
Topics: Adolescent; Diphosphonates; Fractures, Spontaneous; Humans; Hypercalcemia; Male; Osteogenesis Imperf | 1997 |
Intravenous pamidronate treatment in osteogenesis imperfecta.
Topics: Bone Density; Bone Resorption; Calcium; Child; Child, Preschool; Densitometry; Diphosphonates; Femal | 1997 |
Osteogenesis imperfecta: Are fractures and growth hormone treatment linked?
Topics: Child; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Human Growth Hormone; Hum | 1998 |
Use of pamidronate in chronic and acute bone loss conditions.
Topics: Acute Disease; Bone Density; Bone Resorption; Chronic Disease; Diphosphonates; Female; Humans; Male; | 1997 |
Osteogenesis imperfecta--managing brittle bones.
Topics: Child; Diphosphonates; Humans; Osteogenesis Imperfecta; Pamidronate | 1998 |
Bisphosphonate therapy for severe osteogenesis imperfecta.
Topics: Child, Preschool; Diphosphonates; Humans; Infant; Male; Osteogenesis Imperfecta; Pamidronate; Radiog | 2000 |
[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report].
Topics: Age Factors; Alkaline Phosphatase; Bone Density; Diphosphonates; Drug Administration Schedule; Growt | 2001 |
Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Bone Density; Child; Diphosphonates; Dose-Response Relationship, Drug; Femal | 2001 |
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Biomarkers; Bone Density; Bone Remodeling; Child; Child, Prescho | 2002 |
[The association of algodystrophy and Lobstein's disease. Possible value of 3-amino-1-hydroxypropane-1,1-diphosphonic acid].
Topics: Adult; Diphosphonates; Female; Humans; Male; Middle Aged; Osteogenesis Imperfecta; Pamidronate; Refl | 1990 |
Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.
Topics: Child; Diphosphonates; Female; Follow-Up Studies; Humans; Osteogenesis Imperfecta; Pamidronate; Radi | 1987 |